Nepal vs East Timor: Statin use vs. average non-HDL cholesterol levels
Nepal
3.2
in 2018
East Timor
3.2
in 2018
Nepal rank
118th
East Timor rank
118th
Statin use vs. average non-HDL cholesterol levels over time
- Nepal
- East Timor
How they compare
Nepal currently reports 3.2 against 3.2 in East Timor, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Nepal ahead.
Nepal ranks 118th and East Timor ranks 118th of 191 countries.
Across the 4 decades both report, Nepal averaged higher in 3 and East Timor in 1.
Head to head by decade
| Decade | Nepal | East Timor | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.85 | 2.68 | 0.17 | Nepal |
| 1990s | 2.97 | 2.89 | 0.08 | Nepal |
| 2000s | 3.07 | 3.06 | 0.01 | Nepal |
| 2010s | 3.14 | 3.16 | 0.0111 | East Timor |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Nepal or East Timor?
- Nepal, at 3.2 against 3.2 in East Timor as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Nepal and East Timor?
- 0, with Nepal ahead.
- How many years of comparable data are there for Nepal and East Timor?
- 39 years are reported by both, from 1980 to 2018.
- How do Nepal and East Timor rank globally for statin use vs. average non-hdl cholesterol levels?
- Nepal ranks 118th and East Timor ranks 118th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.